Impact of Adjuvant Therapy on Immune Response in Breast Cancer
Author Information
Author(s): C.C. Zielinski, Ch. Muller, E Tichatschek, P. Aiginger
Primary Institution: University Hospital, Vienna, Austria
Hypothesis
Adjuvant chemotherapy and radiotherapy affect T cell activation and soluble interleukin 2 receptor levels in breast cancer patients.
Conclusion
Patients with breast cancer who underwent adjuvant therapy showed significantly lower levels of soluble interleukin 2 receptor after treatment compared to healthy controls.
Supporting Evidence
- Patients with metastatic breast cancer had lower sIL-2R levels compared to healthy controls.
- Adjuvant therapy led to a long-lasting decrease in sIL-2R production.
- Healthy controls produced significantly higher sIL-2R levels than both patient groups.
Takeaway
This study found that breast cancer patients who had treatment with chemotherapy or radiation had lower immune responses compared to healthy people.
Methodology
The study involved measuring soluble interleukin 2 receptor levels in serum and supernatants of stimulated peripheral blood mononuclear cells from breast cancer patients and healthy controls.
Limitations
The study did not assess T cell phenotypes, which may influence the results.
Participant Demographics
54 female patients with breast cancer (mean age: 59.2 years) and 38 healthy female controls.
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.0005
Want to read the original?
Access the complete publication on the publisher's website